Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
15.23
+0.04 (0.26%)
Jun 20, 2025, 4:00 PM - Market closed
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
The 2 analysts that cover Dr. Reddy's Laboratories stock have a consensus rating of "Strong Buy" and an average price target of $16.95, which forecasts a 11.29% increase in the stock price over the next year. The lowest target is $16.9 and the highest is $17.
Price Target: $16.95 (+11.29%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dr. Reddy's Laboratories stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HSBC | HSBC | Hold → Strong Buy Upgrades $14 → $17 | Hold → Strong Buy | Upgrades | $14 → $17 | +10.97% | Jun 5, 2025 |
| Barclays | Barclays | Buy Maintains $17 → $17 | Buy | Maintains | $17 → $17 | +11.62% | Nov 6, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $17 | Buy | Maintains | $16 → $17 | +14.25% | Jul 30, 2024 |
| Barclays | Barclays | Buy Maintains $16 → $16 | Buy | Maintains | $16 → $16 | +6.37% | May 8, 2024 |
| Barclays | Barclays | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +5.06% | Jan 29, 2024 |
Financial Forecast
Revenue This Year
358.87B
from 325.54B
Increased by 10.24%
Revenue Next Year
355.33B
from 358.87B
Decreased by -0.99%
EPS This Year
72.80
from 67.78
Increased by 7.41%
EPS Next Year
58.36
from 72.80
Decreased by -19.83%
Financial currency is INR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 391.8B | 394.9B | 441.1B | |
| Avg | 358.9B | 355.3B | 388.4B | |
| Low | 309.2B | 318.7B | 332.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | 20.3% | 10.0% | 24.1% | |
| Avg | 10.2% | -1.0% | 9.3% | |
| Low | -5.0% | -11.2% | -6.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 93.45 | 86.28 | 85.62 |
| Avg | 72.80 | 58.36 | 63.66 |
| Low | 58.02 | 34.59 | 42.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.9% | 18.5% | 46.7% |
| Avg | 7.4% | -19.8% | 9.1% |
| Low | -14.4% | -52.5% | -26.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.